Vascular Biogenics Ltd. (VBLT)
(Delayed Data from NSDQ)
$1.28 USD
+0.01 (0.79%)
Updated May 3, 2019 03:59 PM ET
After-Market: $1.28 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.28 USD
+0.01 (0.79%)
Updated May 3, 2019 03:59 PM ET
After-Market: $1.28 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Reata (RETA) Plunges on FDA Concerns for Kidney Failure Drug
by Zacks Equity Research
The FDA raises concerns related to data in Reata's (RETA) NDA seeking approval for bardoxolone for treating Alport syndrome. An advisory committee meeting is scheduled tomorrow.
What Makes Vascular Biogenics (VBLT) a New Buy Stock
by Zacks Equity Research
Vascular Biogenics (VBLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Vascular Biogenics (VBLT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 10.00% and -0.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Vascular Biogenics (VBLT) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vascular Biogenics (VBLT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -20.00% and -48.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Vascular Biogenics (VBLT) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vascular Biogenics (VBLT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and -7.50%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Vascular Biogenics (VBLT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -15.38% and 2.50%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Vascular Biogenics (VBLT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vascular Biogenics (VBLT) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vascular Biogenics (VBLT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and 28.67%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 0.00% and -15.05%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Vascular Biogenics (VBLT) Q2 Earnings Expected to Decline
by Zacks Equity Research
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vascular Biogenics (VBLT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 6.25% and 89.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Vascular Biogenics (VBLT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vascular Biogenics (VBLT) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -23.08% and -31.15%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will VBL Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in VBL.
Vascular Biogenics (VBLT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 0.00% and -67.08%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Vascular Biogenics (VBLT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 0.00% and -44.80%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Vascular Biogenics (VBLT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vascular Biogenics (VBLT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -100.00% and -90.48%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Vascular Biogenics (VBLT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vascular Biogenics (VBLT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 41.18% and -53.00%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?